Granzyme K Polyclonal Antibody
- 产品详情
- 实验流程
Application
| WB, IHC-P, IF, ICC, E |
|---|---|
| Primary Accession | P49863 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 28882 Da |
| Gene ID | 3003 |
|---|---|
| Other Names | GZMK; TRYP2; Granzyme K; Fragmentin-3; Granzyme-3; NK-tryptase-2; NK-Tryp-2 |
| Dilution | WB~~Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/20000. Not yet tested in other applications. IHC-P~~1:50~200 IF~~1:50~200 ICC~~N/A E~~N/A |
| Format | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide. |
| Storage Conditions | -20℃ |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | GZMK {ECO:0000303|PubMed:39914456, ECO:0000312|HGNC:HGNC:4711} |
|---|---|
| Function | Serine protease that initiates the GZMK pathway of the complement system, a cascade of proteins directly activated by CD8(+) T-cells that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:3262682, PubMed:39814882, PubMed:39914456). GZMK is specifically secreted by CD8(+) T-cells and mediates both recognition and initiation steps of GZMK complement pathway (PubMed:39914456). First acts as a pattern recognition receptor, which specifically recognizes and binds heparan sulfate glycosaminoglycans on the pathogen surface to drive opsonization (PubMed:39914456). It then initiates the complement pathway cascade by catalyzing cleavage and activation of C2 and C4, the next components of the complement pathway (PubMed:39814882, PubMed:39914456). GZMK-mediated complement activation is an important contributor to tissue inflammation (PubMed:24711407, PubMed:33271118, PubMed:35704599, PubMed:39614076, PubMed:39814882, PubMed:39914456). Also able to cleave and activate F2R/PAR1 and PAR2/F2RL1, possibly promoting interleukin release (PubMed:21760880, PubMed:26936634, PubMed:35881628). May also regulate apoptosis by catalyzing cleavage and activation of BID, thereby promoting cytochrome C release from mitochrondria (PubMed:17308307). |
| Cellular Location | Secreted. Cell surface. Cytoplasmic granule. Note=Constitutively secreted by CD8(+) T-cells in the absence of TCR stimulation (PubMed:39914456) Specifically binds heparan sulfate glycosaminoglycans on the surface of pathogens (PubMed:39914456). |
| Tissue Location | Specifically expressed by CD8(+) T-cells. |
Research Areas
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
¥ 1,250.00
Cat# AP70234
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。